Association complexes between ovalbumin and cyclodextrins have no effect on the immunological properties of ovalbumin

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 57, Issue 2, 2004, Pages 199-205

  Kamphorst, A O ^a   Mendes De Sa I ^a   Faria, A M C ^a   Sinisterra, R D ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Antigenicity; CD, cyclodextrins; CFA, complete Freund's adjuvant; Cyclodextrin; ELISA, enzyme linked immunosorbent assay; I.p., intraperitoneal; Immunization; Oral tolerance; Ova, ovalbumin; Ovalbumin; S.c., subcutaneous

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALPHA CYCLODEXTRIN; AMAIZO; BETA CYCLODEXTRIN; CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; OVALBUMIN; PEPTIDE DERIVATIVE; PROTEIN;

ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG STABILITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY;

EID: 1442286256     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2003.10.019     Document Type: Article

References (24)

1. Peppas N.A., Langer R. New challenges in biomaterials. Science. 263:1994;1715-1720.
2. Langer R. Drug delivery and targeting. Nature. 392:1998;5-10.
3. Langer R. Drug delivery. Drugs on target. Science. 293:2001;58-59.
4. Sinisterra R.D., Shastri V.P., Najjar R., Langer R. Encapsulation and release of rhodium(II) citrate and its association complex with hydroxypropyl-beta-cyclodextrin from biodegradable polymer microspheres. J. Pharm. Sci. 88:1999;574-576.
5. Burgos A.E., Belchior J.C., Sinisterra R.D. Controlled release of rhodium(II) carboxylates and their association complexes with cyclodextrins from hydroxyapatite matrix. Biomaterials. 23:2002;2519-2526.
6. Frezard F., Michalick M.S., Soares C.F., Demicheli C. Novel methods for the encapsulation of meglumine antimoniate into liposomes. Braz. J. Med. Biol. Res. 33:2000;841-846.
7. O'Hagan D.T. Recent developments in vaccine delivery systems. Curr. Drug Targets Infect. Disord. 1:2001;273-286.
8. Uekama K., Hirayama F., Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 98:1998;2045-2076.
9. Beraldo H., Sinisterra R.D., Teixeira L.R., Vieira R.P., Doretto M.C. An effective anticonvulsant prepared following a host-guest strategy that uses hydroxypropyl-beta-cyclodextrin and benzaldehyde semicarbazone. Biochem. Biophys. Res. Commun. 296:2002;241-246.
10. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85:1996;1142-1169.
11. Irie T., Uekama K. Cyclodextrins in peptide and protein delivery. Adv. Drug Deliv. Rev. 36:1999;101-123.
12. Matsubara K., Abe K., Irie T., Uekama K. Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. J. Pharm. Sci. 84:1995;1295-1300.
13. Challacombe S.J., Rahman D., Jeffrey H., Davis S.S., O'Hagan D.T. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology. 76:1992;164-168.
14. Apple R.J., Domen P.L., Muckerheide A., Michael J.G. Cationization of protein antigens. IV. Increased antigen uptake by antigen-presenting cells. J. Immunol. 140:1988;3290-3295.
15. Jain S.L., Barone K.S., Flanagan M.P., Michael J.G. Activation patterns of murine B cells after oral administration of an encapsulated soluble antigen. Vaccine. 14:1996;1291-1297.
16. Faria A.M.C., Weiner H.L. Oral tolerance: mechanisms and therapeutic applications. Adv. Immunol. 73:1999;153-264.
17. Czerkinsky C., Sun J.-B., Lebens M., Li B.-L., Rask C., Lindblad M., Holmgren J. Cholera toxin B subunit as transmucosal carrier-delivery and immunomodulating system for induction of antiinfectious and antipathological immunity. Ann. N. Y. Acad. Sci. 778:1996;185-193.
18. Elson C.O., Tomasi M., Dertzbaugh M.T., Thaggard G., Hunter R., Weaver C. Oral-antigen delivery by way of a multiple emulsion system enhances oral tolerance. Ann. N. Y. Acad. Sci. 778:1996;156-162.
19. Peng H.J., Chang Z.N., Han S.H., Won M.H., Huang B.T. Chemical denaturation of ovalbumin abrogates the induction of oral tolerance of specific IgG antibody and DTH responses in mice. Scand. J. Immunol. 42:1995;297-304.
20. Stransky B., Faria A.M.C., Vaz N.M. Oral tolerance induction with altered forms of ovalbumin. Braz. J. Med. Biol. Res. 31:1998;381-386.
21. Oliveira F.M., Silva-Neto A.F., Silva C.A., Gontijo C.M. Coupling of palmitate to ovalbumin inhibits the induction of oral tolerance. Braz. J. Med. Biol. Res. 31:1998;1421-1424.
22. Kaneko T., Terasawa Y., Senou Y., Nagata M., Kuwata T. Oral tolerance is not influenced by oral application of oil-emulsified proteins. Int. Arch. Allergy Immunol. 116:1998;81-82.
23. Irie T., Otagiri N., Sunada M., Uekama K., Ohtani Y., Yamada Y., Sugiyama Y. Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro. J. Pharmacobio-Dyn. 5:1982;741-744.
24. Ohtani Y., Irie T., Uekama K., Fukunaga K., Pitha J. Differential effects of alpha-, beta- and gamma-cyclodextrins on human erythrocytes. Eur. J. Pharm. Sci. 3:1989;153-162.